Disagree. I've read other analysis where mid market cap companies like Supreme become targets for acquisition. If their bid for CMED falls through, ACB will be far behind what they need come rec. That means they need to buy more instead of grow more of their own. More names pop up on the target list.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.